HARBIN, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that Mr. Stanley Hao, the Company's Chief Financial Officer and Secretary, will be unreachable by investors for a period of time due to health reasons. Until he regains full capacity, investors should contact CCG Investor Relations with any inquiries.
Mr. Yan-qing Liu, China Sky One Medical's Chairman and Chief Executive Officer, commented, "We wish Stanley a speedy recovery. During this time, Mr. Yu-kun Zhang, the Company's Manager of Finance, will continue to assist us with meeting our financial, accounting and reporting needs."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn/ .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the ability of our Manager of Finance to adequately meet our financial, accounting and reporting needs. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Investor Relations Contact: China Sky One Medical Yan-qing Liu, CEO Email: ir@cski.com.cn CCG Investor Relations Crocker Coulson, President Tel: +1-646-213-1915 Email: crocker.coulson@ccgir.com Website: http://www.ccgirasia.com/ Mabel Zhang, Vice President Tel: +1-310-954-1353 Email: mabel.zhang@ccgir.com
China Sky One Medical, Inc.
CONTACT: Company Contact: China Sky One Medical, Inc., Yan-qing Liu, CEO,
ir@cski.com.cn; Investor Relations Contact: CCG Investor Relations, Crocker
Coulson, President, +1-646-213-1915, or crocker.coulson@ccgir.com; Or Ms.
Mabel Zhang, Vice President, +1-310-954-1353, or mabel.zhang@ccgir.com
Web site: http://www.cski.com.cn/
